AU Patent

AU2024365291A1 — New composition for treating spinal muscular atrophy

Assigned to F Hoffmann La Roche AG · Expires 2026-02-19 · 0y expired

What this patent protects

Disclosed herein are pharmaceutical compositions and dosage forms including risdiplam that are useful in the treatment of subjects having SMA. The present disclosure also provides methods for preparing these pharmaceutical compositions and dosage forms, and methods of treating su…

USPTO Abstract

Disclosed herein are pharmaceutical compositions and dosage forms including risdiplam that are useful in the treatment of subjects having SMA. The present disclosure also provides methods for preparing these pharmaceutical compositions and dosage forms, and methods of treating subjects having SMA utilizing the pharmaceutical compositions and dosage forms provided herein.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024365291A1
Jurisdiction
AU
Classification
—
Expires
2026-02-19
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.